278 PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS

largely paid for by Medicaid.Given the recent dramatic change in marijuana laws, our results have substantial implications for public policy.Implementation of guidelines on the diagnosis and management of CHS may help minimize the associated cost and harm.